Cervical cancer poses a substantial threat to women’s health, underscoring the necessity for effective therapeutic agents with low toxicity that specifically target cancer cells. As cancer progresses, increased glucose consumption causes glucose scarcity in the tumor microenvironment (TME). Consequently, it is imperative to identify pharmacological agents capable of effectively killing cancer cells under conditions of low glucose availability within the TME. Previous studies showed that Gboxin, a small molecule, inhibited glioblastoma (GBM) growth by targeting ATP synthase without harming normal cells. However, its effects and mechanisms in cervical cancer cells in low-glucose environments are not clear. This study indicates that Gboxin notably enhanced autophagy, apoptosis, and ferroptosis in cervical cells under low-glucose conditions without significantly affecting cell survival under normal conditions. Further analysis revealed that Gboxin inhibited the activity of complex V and the production of ATP, concurrently leading to a reduction in mitochondrial membrane potential and the mtDNA copy number under low-glucose culture conditions. Moreover, Gboxin inhibited tumor growth under nutrient deprivation conditions in vivo. A mechanistic analysis revealed that Gboxin activated the AMPK signaling pathway by targeting mitochondrial complex V. Furthermore, increased AMPK activation subsequently promoted autophagy and reduced p62 protein levels. The decreased levels of p62 protein facilitated the degradation of Nrf2 by regulating the p62-Keap1-Nrf2 axis, thereby diminishing the antioxidant capacity of cervical cancer cells, ultimately leading to the induction of apoptosis and ferroptosis. This study provides a better theoretical basis for exploring Gboxin as a potential drug for cervical cancer treatment.
Cervical cancer poses a significant threat to women's health, underscoring the critical need for the development of low-toxicity, high-efficacy pharmacological drugs that specifically target cervical cancer cells. During cancer progression, elevated glucose consumption leads to a pervasive state of glucose deficiency within the tumor microenvironment (TME). Consequently, it is imperative to identify pharmacological agents capable of effectively killing cancer cells under conditions of low-glucose availability within the TME. Previous studies have demonstrated that Gboxin, a small molecular compound, effectively inhibited the growth of Glioblastoma (GBM) by targeting the activity of the ATP synthase complex, while exhibiting no detrimental effects on normal cells. However, the role and underlying molecular mechanisms of Gboxin in cervical cancer cells within a low-glucose microenvironment remain inadequately understood. This study suggested that Gboxin significantly promoted autophagy, apoptosis, and ferroptosis of cervical cells under low-glucose conditions while had no obvious effect on cell survival under normal conditons. Further study suggested that Gboxin inhibited mitochondrial function under low-glucose culture conditions while showing no significant changes on glycolysis. Mechanistic analysis revealed that Gboxin inhibited ATP synthesis and activated the AMPK signaling pathway by targeting mitochondrial complex V. Furthermore, the increased AMPK activation subsequently promoted autophagy and reduced p62 protein levels. The decreased levels of p62 protein facilitated the degradation of Nrf2 by regulating p62-Keap1-Nrf2 axis thereby diminishing the antioxidant capacity of cervical cancer cells, ultimately leading to the induction of apoptosis and ferroptosis. This study provided a better theoretical basis for exploring Gboxin as a potential drug for cervical cancer treatment.